GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (LTS:0A4X) » Definitions » Float Percentage Of Total Shares Outstanding

DMK Pharmaceuticals (LTS:0A4X) Float Percentage Of Total Shares Outstanding : 90.91% (As of Jun. 02, 2024)


View and export this data going back to 2020. Start your Free Trial

What is DMK Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, DMK Pharmaceuticals's float shares is 9.17 Mil. DMK Pharmaceuticals's total shares outstanding is 10.09 Mil. DMK Pharmaceuticals's float percentage of total shares outstanding is 90.91%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, DMK Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, DMK Pharmaceuticals's Institutional Ownership is 0.05%.

DMK Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

DMK Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=9.17/10.09
=90.91%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals (LTS:0A4X) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (LTS:0A4X) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
SKYI BBBT STMH DVLP MJNE THCT NEPTF PHBI BLMS GCAN XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
DMK:USA
Address
11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
Website
https://www.adamispharmaceuticals.com
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

DMK Pharmaceuticals (LTS:0A4X) Headlines

No Headlines